ADM and migraine disorder: The CGRP‐related peptides; adrenomedullin and amylin, both of which are able to provoke migraine attacks in patients via the amylin analog pramlintide (with equivalent efficacy to CGRP),156 and intravenous adrenomedullin,157 have also gained interest as possible therapeutic substrates in migraine, providing alternative receptors as targets.